Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Penumbra (NYSE: PEN) reported fourth-quarter 2025 revenue of $385.4M (+22.1%) and full-year 2025 revenue of $1,403.7M (+17.5%). Gross margin improved to 68.0% in Q4 and 67.1% for FY2025. Income from operations was $59.2M in Q4 and $189.2M for FY2025. Net income for Q4 was $47.3M and FY net income was $177.7M. The company will not provide 2026 guidance or host an earnings call due to the proposed acquisition by Boston Scientific (NYSE: BSX).
Positive
- Revenue +22.1% in Q4 2025 to $385.4M
- Full-year revenue +17.5% to $1,403.7M
- Gross margin expanded to 68.0% in Q4 2025
- Income from operations $189.2M for FY2025
Negative
- SG&A rose to $663.4M in FY2025 (+15.6% vs 2024)
- Total operating expenses remained ~53% of revenue in FY2025
- No 2026 guidance due to proposed acquisition by BSX
News Market Reaction – BSX
On the day this news was published, BSX declined 2.22%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BSX is up 1.05% while key device peers are mixed to slightly negative (e.g., SYK -0.77%, MDT -1.82%, ABT -0.41%), suggesting a stock-specific reaction rather than a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Earnings results | Positive | -17.6% | Strong Q4 and 2025 results with double‑digit growth and 2026 guidance. |
| Oct 22 | Earnings results | Positive | +4.0% | Q3 2025 sales and EPS above guidance with raised full‑year outlook. |
| Jul 23 | Earnings results | Positive | +4.5% | Strong Q2 2025 growth, EPS beats, and higher full‑year guidance. |
| Apr 23 | Earnings results | Positive | +4.1% | Q1 2025 revenue and EPS surpassed guidance with robust segment growth. |
| Feb 05 | Earnings results | Positive | +1.4% | Strong Q4 and 2024 results with double‑digit sales and 2025 guidance issued. |
Earnings news has generally been received positively, with one notable negative outlier in early 2026.
Over the last year, Boston Scientific has delivered multiple quarters of double‑digit sales growth, often beating guidance and raising full‑year outlooks. Earnings releases also coincided with an active acquisition strategy, including Penumbra and Valencia Technologies, and several earlier deals. The current Penumbra report showing $385.4M Q4 and $1,403.7M 2025 revenue with strong growth aligns with prior expectations cited when the acquisition was announced, reinforcing the strategic rationale seen across recent earnings updates.
Historical Comparison
Past BSX earnings moves averaged -0.75%. Today’s modest 1.05% gain on Penumbra’s strong 2025 results sits slightly above that pattern.
Earnings releases from 2024–2025 show consistent double‑digit sales growth, repeated guidance raises, and layering in of acquisitions, with Penumbra’s reported $1.4B 2025 revenue fitting the growth profile highlighted in prior BSX updates.
Market Pulse Summary
This announcement details Penumbra’s strong 2025 performance, including Q4 revenue of $385.4M (up 22.1%) and full‑year revenue of $1,403.7M (up 17.5%), with expanding gross and operating margins. The results broadly align with revenue expectations cited when Boston Scientific agreed to acquire Penumbra, reinforcing the growth profile behind the deal. Investors may watch for updates on regulatory approvals, integration progress, and how thrombectomy and embolization growth trends evolve within Boston Scientific’s broader portfolio.
Key Terms
thrombectomy medical
embolization medical
adjusted EBITDA financial
operating margin financial
gross margin financial
constant currency financial
non-GAAP financial measures financial
AI-generated analysis. Not financial advice.
Financial Highlights:
- Revenue of
$385.4 million 22.1% or20.9% in constant currency1, compared to the fourth quarter of 2024. - Revenue of
$1,403.7 million 17.5% or16.9% in constant currency1, compared to the full year 2024. U.S. Thrombectomy revenue of$203.1 million 12.4% compared to the fourth quarter of 2024.U.S. Thrombectomy revenue of$771.5 million 19.3% compared to the full year 2024.- Income from operations of
$59.2 million 15.4% for the fourth quarter of 2025. - Income from operations of
$189.2 million 13.5% for the full year 2025. - Net income of
$47.3 million $79.1 million 12.3% and adjusted EBITDA margin1 of20.5% for the fourth quarter of 2025. - Net income of
$177.7 million $266.8 million 12.7% and adjusted EBITDA margin1 of19.0% for the full year 2025.
Fourth Quarter 2025 Financial Results
Total revenue increased to
Gross profit for the fourth quarter of 2025 was
Total operating expenses were
Income from operations was
Full Year 2025 Financial Results
Total revenue increased to
Gross profit for the year ended December 31, 2025 was
Total operating expenses for the year ended December 31, 2025 were
Income from operations was
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
Full Year 2026 Financial Outlook
Given the proposed acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026.
Webcast and Conference Call Information
Given the proposed acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be hosting a conference call to discuss financial results for the fourth quarter and year ended December 31, 2025.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with
Constant currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into
Non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:
- the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives;
- the excess tax benefits associated with share-based compensation arrangements;
- non-recurring litigation related expenses;
- non-cash long-lived asset impairment related to the impairment of our immersive healthcare asset group; and
- one-time expenses in connection with the wind down of the immersive healthcare business.
Adjusted EBITDA and adjusted EBITDA margin. The Company's adjusted EBITDA reflects the exclusion from GAAP net income of:
- non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges;
- non-operating items such as interest income, interest expense, and provision for income taxes;
- non-recurring litigation related expenses; and
- one-time expenses in connection with the wind down of the immersive healthcare business.
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.
Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees, non-cash long-lived asset impairment charges related to the impairment of our immersive healthcare asset group, and one-time expenses in connection with the wind down of the immersive healthcare business. Further, we consider adjusted EBITDA and adjusted EBITDA margin useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges, non-operating items such as interest income, interest expense, and provision for income taxes, non-recurring litigation related expenses, and one-time expenses in connection with the wind down of the immersive healthcare business.
The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025, which we expect to file with the SEC on or before March 2, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands)
| ||||
December 31, | ||||
2025 | 2024 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 186,897 | $ 324,404 | ||
Marketable investments | 357,919 | 15,727 | ||
Accounts receivable, net | 190,021 | 167,668 | ||
Inventories | 431,549 | 406,737 | ||
Prepaid expenses and other current assets | 50,298 | 36,589 | ||
Total current assets | 1,216,684 | 951,125 | ||
Property and equipment, net | 117,436 | 62,641 | ||
Operating lease right-of-use assets | 173,587 | 177,787 | ||
Finance lease right-of-use assets | 25,972 | 28,018 | ||
Intangible assets, net | 6,186 | 6,513 | ||
Goodwill | 166,750 | 165,826 | ||
Deferred taxes | 79,188 | 100,332 | ||
Other non-current assets | 40,716 | 40,939 | ||
Total assets | $ 1,826,519 | $ 1,533,181 | ||
Liabilities and Stockholders' Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 34,736 | $ 31,326 | ||
Accrued liabilities | 132,163 | 112,429 | ||
Current operating lease liabilities | 13,841 | 12,221 | ||
Current finance lease liabilities | 2,393 | 2,369 | ||
Total current liabilities | 183,133 | 158,345 | ||
Non-current operating lease liabilities | 182,751 | 187,068 | ||
Non-current finance lease liabilities | 20,714 | 21,731 | ||
Other non-current liabilities | 12,318 | 15,106 | ||
Total liabilities | 398,916 | 382,250 | ||
Stockholders' equity: | ||||
Preferred stock | — | — | ||
Common stock | 39 | 38 | ||
Additional paid-in capital | 1,185,525 | 1,096,732 | ||
Accumulated other comprehensive income (loss) | 4,348 | (5,843) | ||
Retained earnings | 237,691 | 60,004 | ||
Total stockholders' equity | 1,427,603 | 1,150,931 | ||
Total liabilities and stockholders' equity | $ 1,826,519 | $ 1,533,181 | ||
Penumbra, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts)
| ||||||||
Three Months Ended December 31, | Year Ended December 31, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
Revenue | $ 385,385 | $ 315,518 | $ 1,403,665 | $ 1,194,615 | ||||
Cost of revenue | 123,257 | 104,797 | 461,228 | 439,620 | ||||
Gross profit | 262,128 | 210,721 | 942,437 | 754,995 | ||||
Operating expenses: | ||||||||
Research and development | 21,794 | 20,010 | 89,766 | 94,783 | ||||
Sales, general and administrative | 181,101 | 147,936 | 663,422 | 573,988 | ||||
Impairment Charge | — | — | — | 76,945 | ||||
Total operating expenses | 202,895 | 167,946 | 753,188 | 745,716 | ||||
Income from operations | 59,233 | 42,775 | 189,249 | 9,279 | ||||
Interest and other income, net | 4,399 | 1,564 | 15,876 | 11,590 | ||||
Income before income taxes | 63,632 | 44,339 | 205,125 | 20,869 | ||||
Provision for income taxes | 16,289 | 10,656 | 27,438 | 6,857 | ||||
Net income | $ 47,343 | $ 33,683 | $ 177,687 | $ 14,012 | ||||
Net income per share: | ||||||||
Basic | $ 1.21 | $ 0.88 | $ 4.57 | $ 0.36 | ||||
Diluted | $ 1.20 | $ 0.86 | $ 4.52 | $ 0.36 | ||||
Weighted average shares outstanding: | ||||||||
Basic | 39,189,828 | 38,418,269 | 38,918,493 | 38,633,744 | ||||
Diluted | 39,392,613 | 39,037,644 | 39,291,828 | 39,268,037 | ||||
Penumbra, Inc. Reconciliation of GAAP Operating Expenses and GAAP Income from Operations to Non-GAAP Operating Expenses and (unaudited) (in thousands)
| ||||||||
Three Months Ended December 31, | Year Ended December 31, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
GAAP operating expenses | $ 202,895 | $ 167,946 | $ 753,188 | $ 745,716 | ||||
GAAP operating expenses include the effect of the following items: | ||||||||
Impairment charge2 | — | — | — | 76,945 | ||||
Wind down expenses3 | — | — | — | 4,971 | ||||
Non-recurring litigation related expenses | — | — | — | 4,823 | ||||
Amortization of finite lived intangible assets acquired | — | — | — | 4,759 | ||||
Non-GAAP operating expenses | $ 202,895 | $ 167,946 | $ 753,188 | $ 654,218 | ||||
GAAP income from operations | $ 59,233 | $ 42,775 | $ 189,249 | $ 9,279 | ||||
GAAP income from operations includes the effect of the following items: | ||||||||
Impairment charge2 | — | — | — | 76,945 | ||||
Wind down expenses3 | — | — | — | 4,971 | ||||
Non-recurring litigation related expenses | — | — | — | 4,823 | ||||
Amortization of finite lived intangible assets acquired | — | — | — | 4,759 | ||||
Non-GAAP income from operations | $ 59,233 | $ 42,775 | $ 189,249 | $ 100,777 | ||||
____________ |
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024. |
3Represents one-time expenses that include severance and other costs related to the wind down of the immersive healthcare business during the three months ended September 30, 2024. |
Penumbra, Inc. Reconciliation of GAAP Net Income and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS1 (unaudited) (in thousands, except per share amounts)
| ||||||||||||||||
Three Months Ended December 31, 2025 | Three Months Ended December 31, 2024 | Year Ended December 31, 2025 | Year Ended December 31, 2024 | |||||||||||||
Net | Diluted | Net | Diluted | Net | Diluted | Net | Diluted | |||||||||
GAAP net income | $ 47,343 | $ 1.20 | $ 33,683 | $ 0.86 | $ 177,687 | $ 4.52 | $ 14,012 | $ 0.36 | ||||||||
GAAP net income includes the effect of the following items: | ||||||||||||||||
Impairment charge2 | — | — | — | — | — | — | 76,945 | 1.96 | ||||||||
Wind down expenses3 | — | — | — | — | — | — | 4,971 | 0.13 | ||||||||
Non-recurring litigation expenses | — | — | — | — | — | — | 4,823 | 0.12 | ||||||||
Amortization of finite lived intangible assets acquired | — | — | — | — | — | — | 4,759 | 0.12 | ||||||||
Tax effect on the non-GAAP adjustments above4 | — | — | — | — | — | — | (22,170) | (0.57) | ||||||||
Excess tax benefits related to stock compensation awards | (830) | (0.02) | (343) | (0.01) | (26,804) | (0.68) | (837) | (0.02) | ||||||||
Non-GAAP net income | $ 46,513 | $ 1.18 | $ 33,340 | $ 0.85 | $ 150,883 | $ 3.84 | $ 82,503 | $ 2.10 | ||||||||
GAAP diluted EPS | $ 1.20 | $ 0.86 | $ 4.52 | $ 0.36 | ||||||||||||
Non-GAAP diluted EPS | $ 1.18 | $ 0.85 | $ 3.84 | $ 2.10 | ||||||||||||
____________ |
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024. |
3Represents one-time expenses that include severance and other costs related to the wind down of the immersive healthcare business during the three months ended September 30, 2024. |
4For the twelve months ended December 31, 2024, management used a combined federal and state tax rate of |
Penumbra, Inc. Reconciliation of GAAP Net Income and GAAP Net Income Margin to Adjusted EBITDA and Adjusted EBITDA Margin1 (unaudited) (in thousands, except for percentages)
| ||||||||
Three Months Ended December 31, | Year Ended December 31, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
GAAP net income | $ 47,343 | $ 33,683 | $ 177,687 | $ 14,012 | ||||
Adjustments to GAAP net income | ||||||||
Depreciation and amortization expense | 4,461 | 4,388 | 17,471 | 23,702 | ||||
Interest income, net | (4,227) | (2,939) | (14,983) | (12,272) | ||||
Provision for income taxes | 16,289 | 10,656 | 27,438 | 6,857 | ||||
Stock-based compensation expense | 15,262 | 12,095 | 59,213 | 46,164 | ||||
Impairment charge2 | — | — | — | 76,945 | ||||
Wind down expenses3 | — | — | — | 4,971 | ||||
Non-recurring litigation related expenses | — | — | — | 4,823 | ||||
Adjusted EBITDA | $ 79,128 | $ 57,883 | $ 266,826 | $ 165,202 | ||||
GAAP revenue | $ 385,385 | $ 315,518 | $ 1,403,665 | $ 1,194,615 | ||||
Adjusted EBITDA | $ 79,128 | $ 57,883 | $ 266,826 | $ 165,202 | ||||
GAAP net income margin | 12.3 % | 10.7 % | 12.7 % | 1.2 % | ||||
Adjusted EBITDA margin | 20.5 % | 18.3 % | 19.0 % | 13.8 % | ||||
____________ |
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024. |
3Represents one-time expenses that include severance and other costs related to the wind down of the immersive healthcare business during the three months ended September 30, 2024. |
Penumbra, Inc. Reconciliation of Revenue Change by Geographic Regions to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages)
| ||||||||||||||
Three Months Ended December 31, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
$ 299,054 | $ 247,917 | $ 51,137 | 20.6 % | $ — | $ 51,137 | 20.6 % | ||||||||
International | 86,331 | 67,601 | 18,730 | 27.7 % | (3,939) | 14,791 | 21.9 % | |||||||
Total | $ 385,385 | $ 315,518 | $ 69,867 | 22.1 % | $ (3,939) | $ 65,928 | 20.9 % | |||||||
Year Ended December 31, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
United States | $ 1,091,761 | $ 902,067 | $ 189,694 | 21.0 % | $ — | $ 189,694 | 21.0 % | |||||||
International | 311,904 | 292,548 | 19,356 | 6.6 % | (7,018) | 12,338 | 4.2 % | |||||||
Total | $ 1,403,665 | $ 1,194,615 | $ 209,050 | 17.5 % | $ (7,018) | $ 202,032 | 16.9 % | |||||||
Penumbra, Inc. Reconciliation of Revenue Change by Product Categories and Geographic Regions to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages)
| ||||||||||||||
Three Months Ended December 31, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | $ 254,696 | $ 220,129 | $ 34,567 | 15.7 % | $ (2,188) | $ 32,379 | 14.7 % | |||||||
Embolization and Access | 130,689 | 95,389 | 35,300 | 37.0 % | (1,751) | 33,549 | 35.2 % | |||||||
Total | $ 385,385 | $ 315,518 | $ 69,867 | 22.1 % | $ (3,939) | $ 65,928 | 20.9 % | |||||||
Year Ended December 31, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | $ 947,918 | $ 815,475 | $ 132,443 | 16.2 % | $ (3,798) | $ 128,645 | 15.8 % | |||||||
Embolization and Access | 455,747 | 379,140 | 76,607 | 20.2 % | (3,220) | 73,387 | 19.4 % | |||||||
Total | $ 1,403,665 | $ 1,194,615 | $ 209,050 | 17.5 % | $ (7,018) | $ 202,032 | 16.9 % | |||||||
Three Months Ended December 31, | Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | ||||||||||||||
$ 203,065 | $ 180,647 | $ 22,418 | 12.4 % | $ — | $ 22,418 | 12.4 % | ||||||||
International | 51,631 | 39,482 | 12,149 | 30.8 % | (2,188) | 9,961 | 25.2 % | |||||||
Total Thrombectomy | 254,696 | 220,129 | 34,567 | 15.7 % | (2,188) | 32,379 | 14.7 % | |||||||
Embolization and Access | ||||||||||||||
95,989 | 67,270 | 28,719 | 42.7 % | — | 28,719 | 42.7 % | ||||||||
International | 34,700 | 28,119 | 6,581 | 23.4 % | (1,751) | 4,830 | 17.2 % | |||||||
Total Embolization and Access | 130,689 | 95,389 | 35,300 | 37.0 % | (1,751) | 33,549 | 35.2 % | |||||||
Total | $ 385,385 | $ 315,518 | $ 69,867 | 22.1 % | $ (3,939) | $ 65,928 | 20.9 % | |||||||
Year Ended December 31, | Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | ||||||||||||||
$ 771,485 | $ 646,711 | $ 124,774 | 19.3 % | $ — | $ 124,774 | 19.3 % | ||||||||
International | 176,433 | 168,764 | 7,669 | 4.5 % | (3,798) | 3,871 | 2.3 % | |||||||
Total Thrombectomy | 947,918 | 815,475 | 132,443 | 16.2 % | (3,798) | 128,645 | 15.8 % | |||||||
Embolization and Access | ||||||||||||||
320,276 | 255,356 | 64,920 | 25.4 % | — | 64,920 | 25.4 % | ||||||||
International | 135,471 | 123,784 | 11,687 | 9.4 % | (3,220) | 8,467 | 6.8 % | |||||||
Total Embolization and Access | 455,747 | 379,140 | 76,607 | 20.2 % | (3,220) | 73,387 | 19.4 % | |||||||
Total | $ 1,403,665 | $ 1,194,615 | $ 209,050 | 17.5 % | $ (7,018) | $ 202,032 | 16.9 % | |||||||
____________ |
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-fourth-quarter-and-full-year-2025-financial-results-302697356.html
SOURCE Penumbra, Inc.
FAQ
What were Penumbra (PEN) revenue results for Q4 2025?
How did Penumbra (PEN) perform for full year 2025 on profit metrics?
Why is Penumbra (PEN) not providing 2026 guidance or hosting an earnings call?
Which product lines drove Penumbra (PEN) revenue growth in 2025?
What investor risks did Penumbra (PEN) disclose in the 2025 results?
